Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 559 of 3330
Next
>>
>
13951 to 13975 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Antibody	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.00000175	uM	7870.018	0.9949	0.9955	2.2478
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.00000877	uM	7870.018	1.0495	1.0434	2.2478
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.0000438	uM	7870.018	1.0048	1.0042	2.2478
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.000219	uM	7870.018	1.0601	1.0526	2.2478
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.0011	uM	7870.018	1.0639	1.0559	2.2478
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.00548	uM	7870.018	1.0272	1.0240	2.2478
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.0274	uM	7870.018	0.9274	0.9341	2.2478
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.137	uM	7870.018	0.6851	0.6903	2.2478
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.685	uM	7870.018	0.4863	0.4513	2.2478
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.00000175	uM	9551.026	1.0287	1.0214	2.6508
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.00000877	uM	9551.026	1.0725	1.0535	2.6508
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.0000438	uM	9551.026	1.0401	1.0299	2.6508
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.000219	uM	9551.026	1.0237	1.0177	2.6508
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.0011	uM	9551.026	1.0490	1.0364	2.6508
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.00548	uM	9551.026	1.0415	1.0309	2.6508
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.0274	uM	9551.026	1.0110	1.0083	2.6508
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.137	uM	9551.026	0.8484	0.8797	2.6508
MCF 10A	NM	Basal B	Cetuximab	EGFR	ErbB	0.685	uM	9551.026	0.6790	0.7282	2.6508
MCF 10F	NM	-	Cetuximab	EGFR	ErbB	0.00000175	uM	7487.102	1.0115	1.0150	1.5273
MCF 10F	NM	-	Cetuximab	EGFR	ErbB	0.00000877	uM	7487.102	1.0005	1.0006	1.5273
MCF 10F	NM	-	Cetuximab	EGFR	ErbB	0.0000438	uM	7487.102	1.0018	1.0023	1.5273
MCF 10F	NM	-	Cetuximab	EGFR	ErbB	0.000219	uM	7487.102	0.9866	0.9825	1.5273
MCF 10F	NM	-	Cetuximab	EGFR	ErbB	0.0011	uM	7487.102	0.9654	0.9544	1.5273
MCF 10F	NM	-	Cetuximab	EGFR	ErbB	0.00548	uM	7487.102	0.9029	0.8706	1.5273
MCF 10F	NM	-	Cetuximab	EGFR	ErbB	0.0274	uM	7487.102	0.9313	0.9089	1.5273

|<
<<
Previous
Page 559 of 3330
Next
>>
>
13951 to 13975 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)